Advaxis, Inc. - “Advaxis Immunotherapies Complement PD-1 Antibodies”

Publishing & Media

Share Tweet

Advaxis, Inc. - “Advaxis Immunotherapies Complement PD-1 Antibodies”

Advaxis Inc. (NASDAQ:ADXS) today published a new blog post on The Chairman’s Blog, written by the company’s CSO, Dr. Robert Petit. is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.

Advaxis CSO, Dr. Robert Petit, published a new blog post about his recent participation in the Bloomberg 2014 State of Healthcare Summit and the future of immunotherapies in cancer treatment. Dr. Petit blogs about “learning that cancer is really an individual disease within each patient” and the work Advaxis is doing with Dr. Khleif to develop an immunotherapy platform that will be complementary to current immunotherapies. Read the full blog post on (

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

ADXS-HPV is currently being evaluated in Phase 1 and 2 clinical trials for HPV-associated cancers: recurrent cervical cancer (completed Phase 2 study conducted in India), locally advanced cervical cancer (GOG/NCI U.S. study, Clinical Identifier NCT01266460), head & neck cancer (CRUK study, Clinical Identifier NCT01598792, Mt. Sinai study, Clinical Identifier NCT02002182), and anal cancer (BrUOG U.S. study, Clinical Identifier NCT01671488). Advaxis has over 15 distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the University of Pennsylvania, the Georgia Regents University Cancer Center, Icahn School of Medicine at Mount Sinai, and others.

For more information please visit:

About is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.